The Market for Medical Devices in Brazil, Russia, India & China

Date: October 22, 2010
US$ 2,965.00
Publisher: Espicom Business Intelligence
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: M164BA54407EN

Download PDF Leaflet

The Market for Medical Devices in Brazil, Russia, India & China
4 separate reports

The BRIC pharmaceutical markets have become increasingly attractive in the portfolio of emerging countries targeted by pharmaceutical companies.

Putting things in perspective...

The BRIC pharmaceutical markets, including pharmacy and hospital sales, are currently valued at US$104.1 billion at retail prices. This market is collectively lower than that found in leading markets such as the USA and Japan, but impressive growth rates mean that pharmaceutical companies have long-term interests in these markets. China, in fact, is expected to become the second leading worldwide pharmaceutical market by 2015.

Sizeable opportunities exist …

There are wide regional health expenditure differences within the BRIC markets, far more than in developed countries where health systems provide a more uniform coverage level. These four countries have a relatively wealthy urban population with a far greater spending power than their respective national average. In the case of China and India, these urban populations have grown rapidly, and number hundreds of millions. The challenge for these countries is to extend this level of wealth to the rest of the population, so that better levels of healthcare become affordable.

A long haul...

This is evolution not revolution, and change is expected to be incremental. Short-term opportunities exist to meet the health demands of the burgeoning middle classes, whilst future prospects are bright, fuelled by strong economic growth. An impressive pharmaceutical market growth projected in BRIC markets is expected to erode some of the commercial differences with the established, but more sluggish, pharmaceutical markets in North America, Japan and Europe.


The pharmacy sector has registered strong growth in 2010. Future OTC sales are expected to be affected by the new dispensing practices, enforced in February 2010. One of the new measures is that OTC medicines can no longer be sold over the counter. Generic sales continue to grow at a higher rate than the overall pharmacy sector, and they are expected to represent 25% of the sector by volume in 2011. Pfizer, whose leading two bestsellers lost their patent in 2010, acquired 40.0% of Teuto in October 2010, in an effort to enhance its position in the generic sector. The company had already signed an agreement with Eurofarma in April 2010.

Russia has a sizeable generic industry, but local production of innovative drugs is negligible. The government intends to change this through the Pharma 2020 strategy, which aims to raise the share of locally produced pharmaceuticals on the market to 50.0% by 2020. The strategy will require an investment of US$5.8 billion over the next decade, mainly from the state, but the government is also trying to encourage international pharmaceutical companies to invest in Russia. One of the goals of the strategy - to remove administrative barriers for drug registration - was addressed in 2010 through the implementation of a more transparent and straightforward registration procedure that is designed to equalise market access for foreign and local companies.

The Indian pharmaceutical industry represents around 8.0% of world pharmaceutical production. Over the last couple of years, Indian firms have been increasingly targeted by multinationals for both collaborative agreements and acquisitions. During 2010, Abbott acquired Piramal Healthcare’s domestic formulations business and formed a commercialisation agreement with Zydus Cadila; AstraZeneca signed a commercialisation agreement with Torrent for a portfolio of generics; and Pfizer has agreed to commercialise biosimilar insulin from Biocon. Pfizer had previously signed commercialisation agreements for off-patent pharmaceuticals with Strides Arcolab, Claris Lifesciences and Aurobindo.

In April 2009, the Chinese government committed US$124.0 billion to develop the country’s healthcare system. The plan is to create a solid platform for universal healthcare access for all by 2020. There are two phases for this plan; Phase 1 from 2009 to 2011 and Phase 2 from 2011 to 2020. The plan revealed that hospitals are often overburdened and the focus needs to shift away from emergency care and serious illness towards primary care, including health promotion, education and disease prevention. Priority will be given to the construction of county level hospitals, township hospitals and community health stations and centres. The government will also fund the construction of village clinics in remote areas so that every village will have at least one unit by the end of the three-year period. A year since the plan’s inception, it has been reported that pharmaceutical sales have increased by more than a quarter.

More Information...
4 Markets Covered

- Brazil
- Russia
- India
- China


Including Espicom's at a glance strategic analysis and key data projections

Political, economic, legal and demographic analysis

Disease burden and prevalence

Organisation, expenditure, infrastructure, services and workforce

Regulatory developments and marketing registration/authorisation



Projections, product development, manufacturing and trade

Trade associations, trade fairs, company intelligence and competitive strategies




Espicom's unique strategic analysis


HEALTHCARE DATA - updated annually

A comprehensive tabula review of the market, including economic indicators, demographics, health expenditure, hospital and primary care data, and healthcare personnel.
Skip to top

Ask Your Question

The Market for Medical Devices in Brazil, Russia, India & China
Company name*:
Contact person*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: